Arcutis Biotherapeutics, Inc.
ARQT
$20.43
-$0.29-1.40%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 259.47M | 208.82M | 166.54M | 110.71M | 74.06M |
| Total Other Revenue | 4.00M | 4.00M | 30.00M | 28.00M | 58.00M |
| Total Revenue | 263.47M | 212.82M | 196.54M | 138.71M | 132.06M |
| Cost of Revenue | 28.73M | 24.70M | 19.13M | 14.47M | 10.15M |
| Gross Profit | 234.74M | 188.12M | 177.41M | 124.24M | 121.91M |
| SG&A Expenses | 249.60M | 238.60M | 229.39M | 220.46M | 209.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 349.30M | 334.12M | 324.94M | 320.64M | 311.83M |
| Operating Income | -85.84M | -121.30M | -128.40M | -181.93M | -179.77M |
| Income Before Tax | -92.33M | -129.12M | -139.39M | -195.19M | -195.39M |
| Income Tax Expenses | 944.00K | 602.00K | 647.00K | 349.00K | 3.37M |
| Earnings from Continuing Operations | -93.27 | -129.72 | -140.04 | -195.54 | -198.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.27M | -129.72M | -140.04M | -195.54M | -198.76M |
| EBIT | -85.84M | -121.30M | -128.40M | -181.93M | -179.77M |
| EBITDA | -80.41M | -116.27M | -126.13M | -179.74M | -178.63M |
| EPS Basic | -0.74 | -1.04 | -1.16 | -1.79 | -2.18 |
| Normalized Basic EPS | -0.46 | -0.65 | -0.72 | -1.12 | -1.33 |
| EPS Diluted | -0.74 | -1.04 | -1.16 | -1.79 | -2.18 |
| Normalized Diluted EPS | -0.46 | -0.65 | -0.72 | -1.12 | -1.33 |
| Average Basic Shares Outstanding | 502.25M | 498.74M | 483.75M | 451.41M | 388.84M |
| Average Diluted Shares Outstanding | 502.25M | 498.74M | 483.75M | 451.41M | 388.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |